{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:06:03Z","timestamp":1787889963891,"version":"build-2784847793"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.intimp.2020.107228","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T22:18:45Z","timestamp":1606429125000},"page":"107228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective"],"prefix":"10.1016","volume":"90","author":[{"given":"Joshua Adedeji","family":"Bolarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy Adaramodu","family":"Oluwatoyosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Iseoluwa","family":"Orege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Ayodeji","family":"Ayeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ajibola","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif Babatunde","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir Bolaji","family":"Tiamiyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanre Anthony","family":"Gbadegesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toluwanimi Oluwadara","family":"Akinyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuks Kenneth","family":"Odoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Happiness Ijeoma","family":"Umeobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adenike Bernice-Eloise","family":"Adeoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.intimp.2020.107228_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.107228_b0010","unstructured":"World Health Organization. Coronavirus disease (COVID-2019) situation reports. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports 30th April 2020."},{"key":"10.1016\/j.intimp.2020.107228_b0015","unstructured":"NHC,2020 [https:\/\/health.nhcgov.com\/yourenvironment\/publichealth\/coronavirus\/nhc-coronavirus-news\/]."},{"key":"10.1016\/j.intimp.2020.107228_b0020","unstructured":"World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Available from: https:\/\/www.who.int\/newsroom\/factsheets\/detail\/middle-east-respiratory-syndrome-coronavirus-(mers-cov) (Accessed 2019)."},{"issue":"10224","key":"10.1016\/j.intimp.2020.107228_b0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.107228_b0030","article-title":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses a statement of the Coronavirus Study Group","author":"Gorbalenya","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.intimp.2020.107228_b0035","first-page":"5","article-title":"Drug firms mobilize to combat the coronavirus outbreak","volume":"98","author":"Jarvis","year":"2020","journal-title":"C&EN"},{"key":"10.1016\/j.intimp.2020.107228_b0040","unstructured":"Nature News. Coronavirus latest: death toll passes 2,000. Available from: https:\/\/www.nature.com\/articles\/d41586-020-00154-w (accessed on 20th Feb 2020)."},{"key":"10.1016\/j.intimp.2020.107228_b0045","unstructured":"ChemDraw Ultra 9.0. CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www. cambridgesoft.com. See Web site for pricing options."},{"key":"10.1016\/j.intimp.2020.107228_b0050","unstructured":"NHC, 2020 [https:\/\/health.nhcgov.com\/yourenvironment\/publichealth\/coronavirus\/nhc-coronavirus-news\/]."},{"issue":"13","key":"10.1016\/j.intimp.2020.107228_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0006-291X(79)91853-9","article-title":"The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA","volume":"89","author":"Goswami","year":"1979","journal-title":"Biochem. Bioph. Res. Co."},{"key":"10.1016\/j.intimp.2020.107228_b0065","doi-asserted-by":"crossref","first-page":"13131317","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0075","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc06-0606","article-title":"A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes","volume":"29","author":"Barnard","year":"2006","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/1568026620999200305145032","article-title":"Effective Chemicals against Novel Coronavirus (COVID-19) in China","volume":"20","author":"Wei","year":"2020","journal-title":"Curr. Top Med Chem."},{"key":"10.1016\/j.intimp.2020.107228_b0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.intimp.2020.107228_b0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Japan Acad. Ser. B: Phys. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"BST"},{"issue":"10","key":"10.1016\/j.intimp.2020.107228_b0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.intimp.2020.107228_b0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107228_b0110","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fphar.2019.01472","article-title":"Efficacy and tolerability of lopinavir\/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1- infected patients in a tertiary care hospital in Beijing, China","volume":"10","author":"Su","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2020.107228_b0120","first-page":"E001","article-title":"Interpretation of \u201cguidelines for the Diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the national health commission (trial version 5)\u201d","volume":"100","author":"Lin","year":"2020","journal-title":"Zhonghua Yixue Zazhi"},{"issue":"2020","key":"10.1016\/j.intimp.2020.107228_b0125","first-page":"200","article-title":"Arbidol\/IFN-a2b therapy for patients with coronavirus disease, a retrospective multicenter cohort study","volume":"22","author":"Ping","year":"2019","journal-title":"Microbes and Infection"},{"key":"10.1016\/j.intimp.2020.107228_b0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0135","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound Library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2020.107228_b0140","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a phosphoramidite prodrug of a pyrrolo[2,1\u2014f][triazin-4-amino]adenine-nucleoside (GS-5374)for the treatment of Ebola and Emerging virus","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem"},{"issue":"396","key":"10.1016\/j.intimp.2020.107228_b0145","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2020.107228_b0150","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.tmaid.2020.101613","article-title":"COVID-19 in Latin America: the implications of the first confirmed case in Brazil","volume":"35","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107228_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the Antiviral Remedsvir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2020.107228_b0165","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107228_b0170","doi-asserted-by":"crossref","unstructured":"T.K. Warren, R. Jordan, M.K. Lo, A.S. Ray, Rl. Mackman, V. Soloveva, Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys 531 (2016) 381-385.","DOI":"10.1038\/nature17180"},{"key":"10.1016\/j.intimp.2020.107228_b0175","doi-asserted-by":"crossref","unstructured":"Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A. Ebola virus relapse causing meningoencephalitis: A case report 338 (2016) 498\u2013503.","DOI":"10.1016\/S0140-6736(16)30386-5"},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","article-title":"Atazanavir: a review of its use in the management of HIV-1 infection","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1358\/dot.2008.44.2.1137107","article-title":"Atazanavir\/ritonavir: a review of its use in HIV therapy","volume":"44","author":"Von Hentig","year":"2008","journal-title":"Drugs Today"},{"key":"10.1016\/j.intimp.2020.107228_b0190","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","article-title":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model","volume":"18","author":"Ram","year":"2020","journal-title":"Computational Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0195","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.intimp.2020.107228_b0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.107228_b0205","first-page":"125","article-title":"Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU) Recent Results","volume":"70","author":"Taguchi","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.107228_b0210","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/srep01035","article-title":"Discovery of highly potent acid ceramidase inhibitors with in vitro tumour chemosensitizing activity","volume":"3","author":"Realini","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.107228_b0215","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3389\/fphar.2019.00818","article-title":"A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS)-induced acute lung injury via inhibition of FAAH and NAAA activities","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1248\/cpb.c19-00895","article-title":"Design and synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as new respiratory syncytial virus fusion protein inhibitors","volume":"68","author":"Yamaguchi-Sasaki","year":"2020","journal-title":"Chem. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet. Infect. Dis"},{"key":"10.1016\/j.intimp.2020.107228_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for 2019 novel coronavirus SARS-CoV-2","author":"Colson","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107228_b0235","article-title":"Teicoplanin potently blocks the cell entry of 2019nCoV [Preprint]","author":"Zhang","year":"2020","journal-title":"Microbiology"},{"key":"10.1016\/j.intimp.2020.107228_b0240","first-page":"1","article-title":"COVID-19: an update on the epidemiological, clinical, preventive, and therapeutic evidence and guidelines of integrative Chinese Western Medicine for the Management of the novel coronavirus","volume":"2020","author":"Chan","year":"2019","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.intimp.2020.107228_b0245","article-title":"A Systematic Review on the Efficacy and Safety of CHlorquine for the Treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.intimp.2020.107228_b0250","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies","author":"Gao","year":"2020","journal-title":"Biosci. Trends in"},{"key":"10.1016\/j.intimp.2020.107228_b0255","doi-asserted-by":"crossref","unstructured":"Rainsford, D. Kim, M.C. Powanda, M.W. Whitehouse, Novel Natural Products: Therapeutic Effects in Pain, Arthritis, and Gastro-intestinal Diseases, Progress in Drug Research 2015 ISBN 978-3-0348-0927-6.","DOI":"10.1007\/978-3-0348-0927-6"},{"key":"10.1016\/j.intimp.2020.107228_b0260","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In-vitro antiviral activity and Projection of Optimized dosing design of the Hydroxychloroquine for the treatment of Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0265","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107228_b0270","first-page":"1","article-title":"Hydroxy chloroquine or chloroquine with or without a Macrolide for treatment of COVID-19: a multinational Registry","author":"Mandeep","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.107228_b0275","first-page":"162","article-title":"Antiviral activity of Emetine dihydrochloride against dengue virus infection","author":"Low","year":"2009","journal-title":"J. Antivirals Antiretroviral"},{"key":"10.1016\/j.intimp.2020.107228_b0280","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2017.06.006","article-title":"Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants","volume":"144","author":"Khandelwal","year":"2017","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.intimp.2020.107228_b0285","first-page":"e00168","article-title":"Erratum for Shen et al., \u201cIdentification of a Novel Enhancer\/Chromatin Opening Element Associated With High-Level \u03b3-Globin Gene Expression\u201d","volume":"39","author":"Shen","year":"2019","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.intimp.2020.107228_b0290","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0295","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3904\/kjim.2018.404","article-title":"Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J. Intern. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0300","article-title":"A new genus of the order actinomycetales","volume":"28","author":"Parenti","year":"1978","journal-title":"Int. J. Systematic Evolutionary Microbiol."},{"issue":"9","key":"10.1016\/j.intimp.2020.107228_b0305","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"issue":"24","key":"10.1016\/j.intimp.2020.107228_b0310","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1093\/hmg\/ddp456","article-title":"Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3","volume":"18","author":"Jung","year":"2009","journal-title":"Hum. Mol. Genet"},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0315","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.biotechadv.2018.02.009","article-title":"Old and new glycopeptide antibiotics: From product to gene and back in the post-genomic era","volume":"36","author":"Marcone","year":"2018","journal-title":"Biotechnol. Adv."},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0320","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s00253-020-10436-y","article-title":"Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes","volume":"104","author":"Yushchuk","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0325","doi-asserted-by":"crossref","first-page":"105944","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of COVID-19?","volume":"55","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107228_b0330","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"15","author":"Takeda","year":"2016","journal-title":"Clin. Pharmacol.: Adv. Appl."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0335","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00294-016-0565-7","article-title":"Core regulatory components of the PHO pathway are conserved in the methylotrophic yeast Hansenula polymorpha","volume":"62","author":"Zhou","year":"2016","journal-title":"Curr Genet"},{"issue":"suppl_2","key":"10.1016\/j.intimp.2020.107228_b0340","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","article-title":"Origin, structure, and activity in vitro and in vivo of dalbavancin","volume":"55","author":"Malabarba","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0345","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.intimp.2020.107228_b0350","article-title":"Teicoplanin potently blocks the cell entry of 2019-nCoV [Preprint]","author":"Zhang","year":"2020","journal-title":"Microbiology"},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0355","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-199040030-00007","article-title":"Teicoplanin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential","volume":"40","author":"Campoli-Richards","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2020.107228_b0360","unstructured":"F. Khamesipour, S.M. Hashemian, P. Tabarsi, A.A. Velayati, A Review of Teicoplanin Used in the Prevention and Treatment of Serious Infections Caused by Gram-Positive Bacteria and Compared Its Effects with Some Other Antibiotics. 8 (2015) 9. DOI: https:\/\/dx.doi.org\/10.13005\/bpj\/641."},{"key":"10.1016\/j.intimp.2020.107228_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/v11100964","article-title":"Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine","author":"Andersen","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.107228_b0370","doi-asserted-by":"crossref","unstructured":"H. Lode, K. Borner, P. Koeppe, T. Schaberg Azithromycin\u2014Review of key chemical, pharmacokinetics and microbiological features 8 (1996) DOI: 10.1093\/jac\/37.suppl_c.1.","DOI":"10.1093\/jac\/37.suppl_C.1"},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0375","first-page":"215","article-title":"Azithromycin (Zithromax\u00ae)","volume":"4","author":"McCarty","year":"1996","journal-title":"Infectious Dis. Obstetrics Gynecol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0380","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/antibiotics5030029","article-title":"From erythromycin to azithromycin and new potential ribosome binding antimicrobials","volume":"5","author":"Jeli\u0107","year":"2016","journal-title":"Antibiotics"},{"key":"10.1016\/j.intimp.2020.107228_b0385","unstructured":"F. Valentin, Azithromycin and COVID-19 History and Review, 2020, DOI: 10.13140\/RG.2.2.33299.63524."},{"issue":"9","key":"10.1016\/j.intimp.2020.107228_b0390","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2020.1787","article-title":"Assessment of QT intervals in a case series of patients with Coronavirus Disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","volume":"5","author":"Bessi\u00e8re","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.intimp.2020.107228_b0395","doi-asserted-by":"crossref","first-page":"100684","DOI":"10.1016\/j.nmni.2020.100684","article-title":"Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance","volume":"35","author":"Choudhary","year":"2020","journal-title":"New Microbes New Infections"},{"key":"10.1016\/j.intimp.2020.107228_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.acvd.2020.04.001","article-title":"Response to the editorial \u201cCOVID-19 in patients with cardiovascular diseases\u201d","author":"Funck-Brentano","year":"2020","journal-title":"Arch. Cardiovascular Diseases"},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0405","article-title":"Should azithromycin be used to treat COVID-19? A rapid review","volume":"4","author":"Gbinigie","year":"2020","journal-title":"BJGP Open"},{"issue":"17","key":"10.1016\/j.intimp.2020.107228_b0410","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.intimp.2020.107228_b0415","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0420","article-title":"Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection","volume":"13","author":"Saleh","year":"2020","journal-title":"Circ: Arrhythmia Electrophysiol."},{"key":"10.1016\/j.intimp.2020.107228_b0425","doi-asserted-by":"crossref","first-page":"104228","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","volume":"145","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cpt.1857","article-title":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID\u201019","volume":"108","author":"Damle","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.107228_b0435","article-title":"Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study [Preprint]","author":"Lane","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2020.107228_b0440","article-title":"Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: Outcomes in hospitalized COVID-19 patients [Preprint]","author":"Carlucci","year":"2020","journal-title":"Infectious Diseases"},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0445","article-title":"African exemplary steps in fighting against COVID-19: A Moroccan example","volume":"9","author":"Addi","year":"2020","journal-title":"Bull. Environ. Pharmacol. Life Sci."},{"key":"10.1016\/j.intimp.2020.107228_b0450","unstructured":"Keskin-Arslan E, Kaplan YC, Koren G. Use of azithromycin during pregnancy and breastfeeding: A coronavirus pandemic (COVID-19) update. 2020;10. Motherisk Int J 2020;1:12."},{"key":"10.1016\/j.intimp.2020.107228_b0455","article-title":"Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: implications for QT interval monitoring [Preprint]","author":"Ramireddy","year":"2020","journal-title":"Cardiovascular Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0460","doi-asserted-by":"crossref","first-page":"106007","DOI":"10.1016\/j.ijantimicag.2020.106007","article-title":"Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin","volume":"55","author":"Derendorf","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107228_b0465","article-title":"A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on the viral carriage in patients with COVID-19 [Preprint]","author":"Hulme","year":"2020","journal-title":"Infectious Diseases (except HIV\/AIDS)"},{"key":"10.1016\/j.intimp.2020.107228_b0470","article-title":"High-risk COVID-19SARS COV-2: potential intervention at multiple points in the COVID-19 disease process via prophylactic treatment with azithromycin or bee derived products [Preprint]","author":"Block","year":"2020","journal-title":"Med. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0475","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1087057110390360","article-title":"An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import","volume":"16","author":"Wagstaff","year":"2011","journal-title":"J. Biomol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0480","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jsfa.2740340304","article-title":"A study of the variability of the endogenous energy output by adult roosters and a determination of the available energy of nine different feedstuffs","volume":"34","author":"Campbell","year":"1983","journal-title":"J. Sci. Food Agric."},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0485","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0490","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of dengue virus (DENV) 1\u20134 nonstructural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin","volume":"99","author":"Tay","year":"2013","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0495","article-title":"Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import","volume":"6","author":"G\u00f6tz","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.intimp.2020.107228_b0500","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of SARS-CoV-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2020.107228_b0505","first-page":"202","article-title":"Nuclear trafficking of proteins from RNA viruses: a potential target for anti-virals","volume":"95","author":"Caly","year":"2012","journal-title":"AntivirRes."},{"key":"10.1016\/j.intimp.2020.107228_b0510","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ceb.2019.01.001","article-title":"Inhibitors of nuclear transport","volume":"58","author":"Jans","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.intimp.2020.107228_b0515","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fmicb.2015.00553","article-title":"Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses","volume":"6","author":"Wulan","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.intimp.2020.107228_b0520","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107228_b0525","unstructured":"O. Peri\u0161i\u0107, Recognition of potential Covid-19 drug treatments through the study of existing protein-drug and protein-protein structures: an analysis of kinetically active residues (n.d.) 18."},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"Wu","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.intimp.2020.107228_b0535","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view [Preprint]","author":"Momekov","year":"2020","journal-title":"Infect. Dis. (except HIV\/AIDS)"},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0540","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and treatment?","volume":"82","author":"Patr\u00ec","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.107228_b0545","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and Novel Coronavirus Disease (COVID-19): keeping rigor in times of urgency","author":"Chaccour","year":"2020","journal-title":"Am. J. Tropical Med. Hygiene"},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0550","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ijtb.2020.07.031","article-title":"White paper on Ivermectin as a potential therapy for COVID-19","volume":"67","author":"Vora","year":"2020","journal-title":"Indian J. Tuberculosis"},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0555","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/cpt.1889","article-title":"The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID\u201019","volume":"108","author":"Schmith","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.107228_b0560","article-title":"Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques [Preprint]","author":"Vanachayangkul","year":"2020","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2020.107228_b0565","unstructured":"Muzaffar A, Brossi A. Chemistry of colchicine. New York., 1996;5."},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0570","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2020.107228_b0575","series-title":"Cytotoxicity","author":"Kurek","year":"2018"},{"issue":"3","key":"10.1016\/j.intimp.2020.107228_b0580","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014Update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0585","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00044-012-0077-z","article-title":"Colchicine and its various physicochemical and biological aspects","volume":"22","author":"Sapra","year":"2013","journal-title":"Med. Chem. Res."},{"issue":"5","key":"10.1016\/j.intimp.2020.107228_b0590","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ni.2550","article-title":"Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome","volume":"14","author":"Misawa","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2020.107228_b0595","doi-asserted-by":"crossref","first-page":"102468","DOI":"10.1016\/j.jaut.2020.102468","article-title":"The anti-viral facet of anti-rheumatic drugs: lessons from COVID-19","volume":"111","author":"Perricone","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0600","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.hjc.2020.03.002","article-title":"The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design","volume":"61","author":"Deftereos","year":"2020","journal-title":"Hellenic J. Cardiol."},{"key":"10.1016\/j.intimp.2020.107228_b0605","doi-asserted-by":"crossref","DOI":"10.4081\/itjm.2020.1284","article-title":"Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia","author":"Vitiello","year":"2020","journal-title":"Italian J. Med."},{"key":"10.1016\/j.intimp.2020.107228_b0610","first-page":"m1091","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019","author":"Chen","year":"2020","journal-title":"Retrospective Study"},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0615","doi-asserted-by":"crossref","first-page":"4","DOI":"10.34172\/jpe.2020.02","article-title":"Possible ameliorative effect of colchicine on the prevention of cytokine storm and its associated hyper-inflammation in patients with COVID-19","volume":"5","author":"Keikhaei","year":"2020","journal-title":"J. Prev. Epidemiol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107228_b0620","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10067-020-05144-x","article-title":"Colchicine may not be effective in COVID-19 infection; it may even be harmful?","volume":"39","author":"Cumhur Cure","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107228_b0625","doi-asserted-by":"crossref","first-page":"102566","DOI":"10.1016\/j.autrev.2020.102566","article-title":"Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis","volume":"19","author":"Gendelman","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0630","doi-asserted-by":"crossref","DOI":"10.14214\/sf.7803","article-title":"Reflections on the number of independent solutions for forest spatial harvest scheduling problems: a case of simulated annealing","volume":"52","author":"Dong","year":"2018","journal-title":"Silva Fenn."},{"issue":"1361\u20131367","key":"10.1016\/j.intimp.2020.107228_b0635","article-title":"Homoharringtonine in Combination with cytarabine and aclarubicin resulted in a high complete remission rate after the first induction therapy in a patient with denovo acute myeloid leukaemia","volume":"20","author":"Jin","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2020.107228_b0640","article-title":"Wang jianmin Homoharringtonine and omacetaxine for myeloid haematological malignancies","volume":"7","author":"Shuqing","year":"2014","journal-title":"J. Haematol. Oncol."},{"key":"10.1016\/j.intimp.2020.107228_b0645","unstructured":"FDA 2012 [https:\/\/www.usa.gov\/federal-agencies\/food-and-drug-administration] Assessed."},{"issue":"11","key":"10.1016\/j.intimp.2020.107228_b0650","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/v10110601","article-title":"The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo","volume":"10","author":"Dong","year":"2018","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0655","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","article-title":"Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumours","volume":"71","author":"Nemunaitis","year":"2013","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"17","key":"10.1016\/j.intimp.2020.107228_b0660","first-page":"4180","article-title":"Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2","volume":"59","author":"Lin","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.107228_b0665","article-title":"Alpha 1 antitrypsin is an inhibitor of the SARS-CoV2\u2013priming protease TMPRSS2 [Preprint]","author":"Azouz","year":"2020","journal-title":"Microbiology"},{"key":"10.1016\/j.intimp.2020.107228_b0670","article-title":"COVID 19: camostat and the role of serine protease entry inhibitor TMPRSS2","author":"Bittmann","year":"2020","journal-title":"J. Regenerative Biol. Med."},{"key":"10.1016\/j.intimp.2020.107228_b0675","article-title":"Ontological and bioinformatics analysis of anti-coronavirus drugs and their implication for drug repurposing against COVID-19 [Preprint]","author":"Liu","year":"2020","journal-title":"Med. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0680","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/2159-8290.CD-20-0451","article-title":"TMPRSS2 and COVID-19: serendipity or opportunity for intervention?","volume":"10","author":"Stopsack","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2020.107228_b0685","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","author":"Hoffmann","year":"2020","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"10.1016\/j.intimp.2020.107228_b0690","doi-asserted-by":"crossref","unstructured":"K. Sonawane, S.S. Barale, M.J. Dhanavade, S.R. Waghmare, N.H. Nadaf, S.A. Kamble, A.A. Mohammed, A.M. Makandar, P.M. Fandilolu, A.S. Dound, N.M. Naik, Homology Modeling and Docking Studies of TMPRSS2 with Experimentally Known Inhibitors Camostat Mesylate, Nafamostat, and Bromhexine Hydrochloride to Control SARS-Coronavirus-2, 2020 [Preprint]. https:\/\/doi.org\/10.26434\/chemrxiv.12162360.v1.","DOI":"10.26434\/chemrxiv.12162360.v1"},{"key":"10.1016\/j.intimp.2020.107228_b0695","article-title":"ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study [Preprint]","author":"Gill","year":"2020","journal-title":"Genetic Genomic Med."},{"key":"10.1016\/j.intimp.2020.107228_b0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46570\/utjms.vol7-2020-361","article-title":"COVID-19 pandemic; Transmembrane Protease Serine 2 (TMPRSS2) inhibitors as potential therapeutics for SARS-CoV-2 coronavirus","volume":"7","author":"Jankun","year":"2020","journal-title":"6. UTJMS"},{"key":"10.1016\/j.intimp.2020.107228_b0705","article-title":"Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations [Preprint]","author":"Russo","year":"2020","journal-title":"Genetics"},{"key":"10.1016\/j.intimp.2020.107228_b0710","article-title":"TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets [Preprint]","author":"Bestle","year":"2020","journal-title":"Microbiology"},{"key":"10.1016\/j.intimp.2020.107228_b0715","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with Lopinavir\/ritonavir or interferon-Beta1b improves the outcome of MERS-CoV infection in a no human primate model of the common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect Dis."},{"key":"10.1016\/j.intimp.2020.107228_b0720","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronavirus drug discovery and therapeutics options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drugs Discovery"},{"issue":"5","key":"10.1016\/j.intimp.2020.107228_b0725","doi-asserted-by":"crossref","first-page":"e20200653","DOI":"10.1084\/jem.20200653","article-title":"COVID-19 and emerging viral infections: the case for interferon lambda","volume":"217","author":"Prokunina-Olsson","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0730","first-page":"e12465","article-title":"COVID 19: Lambda interferon against viral load and hyperinflammation","volume":"12","author":"Andreakos","year":"2020","journal-title":"Mol. Med."},{"key":"10.1016\/j.intimp.2020.107228_b0735","article-title":"Single-cell RNA-seq identifies cell subsets in human placenta that highly expresses factors to drive pathogenesis of SARS-CoV-2 [Preprint]","author":"Ashray","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2020.107228_b0740","article-title":"No evidence of SARS-CoV-2 in the semen of males recovering from COVID-19","author":"Pan","year":"2020","journal-title":"Fertil. Steril."},{"issue":"1","key":"10.1016\/j.intimp.2020.107228_b0745","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04382-3","article-title":"Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Irvani","year":"2020","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0750","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3201\/eid1004.030458","article-title":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs","volume":"10","author":"Tan","year":"2004","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107228_b0755","doi-asserted-by":"crossref","unstructured":"Ivan Fan-Ngai Hung, Kwok-Cheung Lung, Eugene Yuk-Keung Tso, Raymond Liu, Tom Wai-Hin Chung, Man-Yee Chu, Yuk-Yung Ng, Jenny Lo, et al, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet 395 (2020) https:\/\/doi.org\/10.1016\/S0140-6736(20)31042-4.","DOI":"10.1016\/S0140-6736(20)31042-4"},{"key":"10.1016\/j.intimp.2020.107228_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable molecular mechanism of remdesivir for the treatment of COVID-19","author":"Saha","year":"2020","journal-title":"Arch. Med. Res. (Elsevier)"},{"key":"10.1016\/j.intimp.2020.107228_b0765","article-title":"Atazanavir inhibits SARSCoV-2 replication and pro-inflammatory cytokine production","author":"Fintelman","year":"2020","journal-title":"BioRxiv"},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0770","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"10.1016\/j.intimp.2020.107228_b0775","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00023-19","article-title":"High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses","volume":"93","author":"Shen","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.107228_b0780","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.intimp.2020.107228_b0785","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"8","key":"10.1016\/j.intimp.2020.107228_b0790","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1513\/AnnalsATS.202004-309SD","article-title":"Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial","volume":"17","author":"Brown","year":"2020","journal-title":"Annals ATS"},{"issue":"4","key":"10.1016\/j.intimp.2020.107228_b0795","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40495-020-00225-6","article-title":"Colchicine in COVID-19: an old drug, new use","volume":"6","author":"Schlesinger","year":"2020","journal-title":"Curr. Pharmacol Rep"},{"issue":"12","key":"10.1016\/j.intimp.2020.107228_b0800","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00228-020-02963-4","article-title":"Inhibition of SARS-CoV-2 entry through the ACE2\/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies","volume":"76","author":"Ragia","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107228_b0805","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III Interferons \u2013 induction, signaling, evasion, and application to Combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.intimp.2020.107228_b0810","doi-asserted-by":"crossref","unstructured":"I.G. Faiq, M. Sabeeh, M.S. Hend, D.D. Basim, M. Marwan, AlMashhadani, et al., Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) medRxiv preprint, DOI: https:\/\/doi.org\/10.1101\/2020.07.07.20145979, doi: medRxiv preprint.","DOI":"10.1101\/2020.07.07.20145979"},{"issue":"17","key":"10.1016\/j.intimp.2020.107228_b0815","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome\/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692033695X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692033695X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:30:59Z","timestamp":1744936259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692033695X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":163,"alternative-id":["S156757692033695X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107228","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107228"}}